头孢唑林与R1侧链:为何头孢菌素过敏患者在接受关节置换术时可安全使用头孢唑林
该研究回顾了2016至2024年间在单一学术中心接受髋或膝关节置换术且记录有头孢菌素过敏的1268例患者,比较接受头孢唑林(482例)与替代抗生素预防(786例)者术后72小时内IgE介导或严重IV型超敏反应的发生率,结果为0.0%对0.51%(p=0.30),结论认为头孢唑林与0.0%的过敏反应发生率相关。
要点
- 头孢唑林组术后72小时内IgE介导或严重IV型过敏反应发生率为0.0%(0/482),替代抗生素组为0.51%(4/786),两组差异无统计学显著(p=0.30)。
- 初次关节置换术后假体周围感染率头孢唑林组0.21%对替代抗生素组0.26%(p=0.83),无显著差异。
- 头孢唑林组1例出现轻度自限性尿道刺激,替代抗生素组5例出现抗生素相关不良事件。
核心结论
- 在因头孢菌素过敏而接受关节置换术的患者队列中,使用头孢唑林与0.0%的IgE介导或严重IV型过敏反应发生率相关。
研究设计与样本
- 回顾性队列研究,纳入2016至2024年间在一所高手术量学术中心接受全髋或全膝关节置换术且记录有头孢菌素过敏的患者共1268例,其中接受头孢唑林者482例,接受替代抗生素预防者786例。
主要发现
- 术后72小时内IgE介导或伴终末器官功能障碍的严重IV型超敏反应发生率:头孢唑林组0.0%(0/482)对替代抗生素组0.51%(4/786),p=0.30。
- 初次关节置换术后假体周围感染率:头孢唑林组0.21%对替代抗生素组0.26%,p=0.83。
- 艰难梭菌感染率:头孢唑林组0.0%对替代抗生素组0.0%。
- 90天内再入院率:头孢唑林组3.95%对替代抗生素组4.33%,p=0.75。
- 头孢唑林组1例出现轻度自限性尿道刺激;替代抗生素组5例出现抗生素相关不良事件,包括皮肤反应、胃肠道不适、胰腺炎和头痛。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cefazolin, a first-generation cephalosporin, is the standard antibiotic for perioperative prophylaxis in patients undergoing hip or knee arthroplasty. Research has demonstrated significantly higher periprosthetic joint infection (PJI) rates when non-cefazolin antibiotics are used for prophylaxis. Notably, cefazolin contains an R1 side chain that has not shown cross-reactivity with other cephalosporins. However, in patients with a reported cephalosporin allergy, there is often uncertainty about the optimal antibiotic choice. This study aimed to determine the safety of perioperative cefazolin in patients with a documented cephalosporin allergy undergoing joint arthroplasty. METHODS: We reviewed the records of 1,268 patients who had a documented cephalosporin allergy and underwent total hip or knee arthroplasty at a high-volume academic center from 2016 to 2024. We compared patients who received cefazolin despite a cephalosporin allergy (n = 482) and patients who received an alternative antibiotic prophylaxis (n = 786). The primary outcome was the incidence of immunoglobulin E (IgE)-mediated allergic reactions or "severe" Type-IV delayed hypersensitivity reactions with end organ dysfunction within 72 hours postoperatively. The secondary outcomes included 90-day rates of complications including PJI, Clostridioides difficile infections, adverse events related to the antibiotic, and readmission. RESULTS: The incidence of an allergic reaction in patients with an allergy to cephalosporin who received cefazolin was 0.0% (0 of 482) compared with 0.51% (4 of 786) in patients who received an alternative antibiotic prophylaxis (p = 0.30). There were no significant differences in the rates of PJI after primary arthroplasty (0.21% compared with 0.26%; p = 0.83), C. difficile infection (0.0% compared with 0.0%), or readmission within 90 days (3.95% compared with 4.33%; p = 0.75). One patient who received cefazolin experienced mild, self-limited urethral irritation. Five patients receiving alternative antibiotics experienced antibiotic-related adverse events, including skin reactions, gastrointestinal distress, pancreatitis, and headache. CONCLUSIONS: In this cohort of patients undergoing joint arthroplasty, cefazolin administration in patients with a cephalosporin allergy was associated with a 0.0% incidence of IgE-mediated or severe Type-IV allergic reactions. LEVEL OF EVIDENCE: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
引用
- Jolissaint JE, Mallett KE, Thomson AL, et al. Cefazolin and the R1 Side Chain: Why Patients with a Cephalosporin Allergy Can Be Safely Given Cefazolin While Undergoing Joint Arthroplasty. J Bone Joint Surg Am. 2026. PMID: 41592154. doi:10.2106/JBJS.25.01349
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。